Drug developers GlaxoSmithKline plc and CureVac NV have announced plans to work jointly on vaccines against emerging Covid-19 variants of the coronavirus. In addition, GSK will help manufacture up to 100 million doses of CureVac’s first-generation Covid-19 vaccine candidate.
Read More
